Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial

作者
Mariana Cannellotto,Mariano Duarte,Guillermo Alberto Keller,Ramiro Larrea,Eleonora Cunto,Viviana Chediack,Mariela Mansur,Daniela M Brito,Elizabeth García,H. E. Di Salvo,Fabrizio Verdini,Cecilia Domínguez,Liliana Jordá Vargas,Javier Eugenio Roberti,Guillermo Di Girolamo,Esteban J. Estrada
出处
期刊:Emergency Medicine Journal [BMJ]
卷期号:39 (2): 88-93 被引量:39
标识
DOI:10.1136/emermed-2021-211253
摘要

Background Hyperbaric oxygen (HBO2) therapy has been proposed to treat hypoxaemia and reduce inflammation in COVID-19. Our objective was to analyse safety and efficacy of HBO2in treatment of hypoxaemia in patients with COVID-19 and evaluate time to hypoxaemia correction. Methods This was a multicentre, open-label randomised controlled trial conducted in Buenos Aires, Argentina, between July and November 2020. Patients with COVID-19 and severe hypoxaemia (SpO2≤90% despite oxygen supplementation) were assigned to receive either HBO2treatment or the standard treatment for respiratory symptoms for 7 days. HBO2treatment was planned for ≥5 sessions (1 /day) for 90 min at 1.45 atmosphere absolute (ATA). Outcomes were time to normalise oxygen requirement to SpO2≥93%, need for mechanical respiratory assistance, development of acute respiratory distress syndrome and mortality within 30 days. A sample size of 80 patients was estimated, with a planned interim analysis after determining outcomes on 50% of patients. Results The trial was stopped after the interim analysis. 40 patients were randomised, 20 in each group, age was 55.2±9.2 years. At admission, frequent symptoms were dyspnoea, fever and odynophagia; SpO2was 85.1%±4.3% for the whole group. Patients in the treatment group received an average of 6.2±1.2 HBO2sessions. Time to correct hypoxaemia was shorter in treatment group versus control group; median 3 days (IQR 1.0–4.5) versus median 9 days (IQR 5.5–12.5), respectively (p<0.010). OR for recovery from hypoxaemia in the HBO2group at day 3 compared with the control group was 23.2 (95% CI 1.6 to 329.6; p=0.001) Treatment had no statistically significant effect on acute respiratory distress syndrome, mechanical ventilation or death within 30 days after admission. Conclusion Our findings support the safety and efficacy of HBO2in the treatment of COVID-19 and severe hypoxaemia. Trial registration number NCT04477954 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
顺心的大碗完成签到 ,获得积分10
1秒前
June17完成签到,获得积分10
1秒前
称心的乐巧完成签到,获得积分10
2秒前
2秒前
Hello的应助被烊烊采纳,获得10
2秒前
搜集达人的应助被katha采纳,获得10
2秒前
V1G1L完成签到,获得积分10
2秒前
ding的应助被Lifel采纳,获得10
3秒前
十八与雨完成签到,获得积分10
3秒前
3秒前
大个的应助被负责银耳汤采纳,获得10
3秒前
ws完成签到,获得积分10
3秒前
3秒前
长生久视完成签到,获得积分10
4秒前
joy发布了新的文献求助10
4秒前
蒋老黑发布了新的文献求助10
4秒前
5秒前
5秒前
5秒前
申屠发布了新的文献求助10
5秒前
5秒前
5秒前
lyy发布了新的文献求助10
5秒前
5秒前
其实发布了新的文献求助10
5秒前
Zoey完成签到 ,获得积分20
6秒前
6秒前
桐桐的应助被初景采纳,获得30
6秒前
可爱的函函的应助被blingbling采纳,获得10
6秒前
6秒前
彭于彦祖的应助被lulululu采纳,获得50
6秒前
Eviyen发布了新的文献求助20
6秒前
羔羔羊发布了新的文献求助30
7秒前
秋风的应助被激你肽酶采纳,获得10
7秒前
Henry发布了新的文献求助10
7秒前
7秒前
领导范儿的应助被英勇的若灵采纳,获得10
7秒前
图图完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155816
求助须知:如何正确求助?哪些是违规求助? 9552109
关于积分的说明 21708107
捐赠科研通 7744978
什么是DOI,文献DOI怎么找? 3426225
关于科研通互助平台的介绍 2551237
邀请新用户注册赠送积分活动 2469958